HWEE-YONG YAP, M.D.; GEORGE R. BLUMENSCHEIN, M.D.; FRANK C. SCHELL, M.D.; AMAN U. BUZDAR, M.D.; MANUEL VALDIVIESO, M.D.; GERALD P. BODEY, M.D.
Thirty-one patients who had metastatic breast cancer extensively pretreated with combination chemotherapy, including doxorubicin, were treated with dihydroxyanthracenedione, 3 to 4 mg/m2 body surface are a daily for 5 consecutive days every 4 weeks. Of 27 evaluable patients, one achieved a complete response and five had partial responses. Furthermore, responses were seen in patients who were refractory to doxorubicin, indicating a lack of cross-resistance between doxorubicin and dihydroxyanthracenedione. Acute drug toxicity was insignificant except for severe granulocytopenia at the dose level of 4 mg/m2 · d. The median duration of remission had not been reached, but was more than 26 weeks, with four of the six responding patients still in remission at last follow-up. We believe that dihydroxyanthracenedione has significant activity against refractory metastatic breast cancer and further evaluation is warranted.
YAP H, BLUMENSCHEIN GR, SCHELL FC, BUZDAR AU, VALDIVIESO M, BODEY GP. Dihydroxyanthracenedione: A Promising New Drug in the Treatment of Metastatic Breast Cancer. Ann Intern Med. ;95:694–697. doi: 10.7326/0003-4819-95-6-694
Download citation file:
Published: Ann Intern Med. 1981;95(6):694-697.
Breast Cancer, Hematology/Oncology, Multiple Sclerosis, Neurology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use